NASDAQ: CDNA
Caredx Inc Stock

$22.97-0.69 (-2.92%)
Updated Jun 12, 2026
CDNA Price
$22.97
Fair Value Price
-$1.68
Market Cap
$1.19B
52 Week Low
$10.96
52 Week High
$24.13
P/E
-143.56x
P/B
3.78x
P/S
2.15x
PEG
N/A
Dividend Yield
N/A
Revenue
$412.82M
Earnings
-$8.19M
Gross Margin
68.9%
Operating Margin
-3.95%
Profit Margin
-2%
Debt to Equity
0.31
Operating Cash Flow
$73M
Beta
1.59
Next Earnings
Aug 5, 2026
Ex-Dividend
N/A
Next Dividend
N/A

CDNA Overview

CareDx, Inc. is a global innovator specializing in the discovery, development, and commercialization of diagnostic and management tools designed for transplant recipients and their healthcare providers. The company's extensive portfolio features a range of specialized diagnostic solutions for organ monitoring, including: AlloSure Kidney, AlloSure Heart, and AlloSure Lung: Advanced tests employing donor-derived cell-free DNA (dd-cfDNA) technology to assess the health of kidney, heart, and lung transplants, respectively. AlloMap Heart: A gene expression-based solution specifically for heart transplant patients. AlloSeq cfDNA: A broader surveillance tool to measure dd-cfDNA levels in the blood. CareDx also provides cutting-edge human leukocyte antigen (HLA) typing technologies, such as TruSight HLA, an NGS-based high-resolution typing solution; Olerup SSP, which uses sequence-specific primer technology for HLA allele typing; QTYPE for precise HLA typing; and AlloSeq Tx, another high-resolution HLA typing offering. For stem cell transplant recipients, the company offers AlloSeq HCT for chimerism testing. Beyond diagnostics, CareDx develops vital software and digital platforms to streamline transplant patient management. These include Ottr, a dedicated transplant patient management software; XynQAPI, focused on transplant quality tracking and waitlist management; and AlloCare, a mobile application serving as a patient-centric resource for those who have undergone transplantation. The company distributes its products directly to clients, as well as through a network of third-party distributors and sub-distributors. CareDx has forged significant partnerships, including a licensing agreement with Illumina, Inc. for the distribution, development, and commercialization of next-generation sequencing (NGS) products and technologies. Additionally, it collaborates with Cibiltech SAS to commercialize iBox, a software designed for the predictive analysis of kidney allograft loss post-transplantation. Founded in 1998, the company was initially known as XDx, Inc. before rebranding to CareDx, Inc. in March 2014. Its headquarters are located in South San Francisco, California.

Zen Rating

Our proven quant model uses 115 proprietary factors, including AI, to determine CDNA's potential to beat the market

AStrong Buy
  • Stocks with a Zen Rating of Strong Buy (A) had an average return of +32.52% per year. Learn More

Zen Rating Component Grades

C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.

Industry: Diagnostic & Research

Industry Rating
C
CDNA
Ranked
#1 of 44

Top Ranked Stocks in Industry

Name / TickerPriceZen Rating
$129.84B
$16.19B
$101.12B
View Top Diagnostic & Research Stocks

Be the first to know about important CDNA news, forecast changes, insider trades & much more!

CDNA News

Overview

Due Diligence Score

Industry Average (27)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how CDNA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

CDNA ($22.97) is overvalued by 1,468.42% relative to our estimate of its Fair Value price of -$1.68 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
CDNA ($22.97) is not significantly undervalued (1,468.42%) relative to our estimate of its Fair Value price of -$1.68 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
CDNA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more CDNA due diligence checks available for Premium users.

Valuation

CDNA fair value

Fair Value of CDNA stock based on Discounted Cash Flow (DCF)

Price
$22.97
Fair Value
-$1.68
Undervalued by
1,468.42%
CDNA ($22.97) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
CDNA ($22.97) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
CDNA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

CDNA price to earnings (PE)

For valuing profitable companies with steady earnings

Company
-143.56x
Industry
16.39x
Market
14.15x

CDNA price to book (PB)

For valuing companies that are loss-making or have lots of physical asset

Company
3.78x
Industry
3.51x
CDNA is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation

CDNA's financial health

Profit margin

Revenue
$117.7M
Net Income
$2.8M
Profit Margin
2.4%
CDNA's Earnings (EBIT) of -$16.31M... subscribe to Premium to read more.
Interest Coverage Financials
CDNA's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$411.1M
Liabilities
$97.5M
Debt to equity
0.31
CDNA's short-term assets ($269.40M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CDNA's short-term assets ($269.40M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CDNA's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
CDNA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
$4.3M
Investing
$11.1M
Financing
-$2.9M
CDNA's operating cash flow ($72.95M)... subscribe to Premium to read more.
Debt Coverage Financials

CDNA vs Diagnostic & Research Stocks

TickerZen RatingMarket Cap1d %P/EP/B
CDNAA$1.19B-2.92%-143.56x3.78x
OPKC$1.07B-2.07%-5.26x0.89x
PSNLD$1.00B+1.80%-9.40x3.94x
NEOC$1.45B-2.79%-14.67x1.75x
CSTLD$627.83M-1.48%-49.29x1.36x

Caredx Stock FAQ

What is Caredx's quote symbol?

(NASDAQ: CDNA) Caredx trades on the NASDAQ under the ticker symbol CDNA. Caredx stock quotes can also be displayed as NASDAQ: CDNA.

If you're new to stock investing, here's how to buy Caredx stock.

What is the 52 week high and low for Caredx (NASDAQ: CDNA)?

(NASDAQ: CDNA) Caredx's 52-week high was $24.13, and its 52-week low was $10.96. It is currently -4.81% from its 52-week high and 109.58% from its 52-week low.

How much is Caredx stock worth today?

(NASDAQ: CDNA) Caredx currently has 51,659,481 outstanding shares. With Caredx stock trading at $22.97 per share, the total value of Caredx stock (market capitalization) is $1.19B.

Caredx stock was originally listed at a price of $9.05 in Jul 17, 2014. If you had invested in Caredx stock at $9.05, your return over the last 11 years would have been 153.81%, for an annualized return of 8.84% (not including any dividends or dividend reinvestments).

How much is Caredx's stock price per share?

(NASDAQ: CDNA) Caredx stock price per share is $22.97 today (as of Jun 12, 2026).

What is Caredx's Market Cap?

(NASDAQ: CDNA) Caredx's market cap is $1.19B, as of Jun 14, 2026.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Caredx's market cap is calculated by multiplying CDNA's current stock price of $22.97 by CDNA's total outstanding shares of 51,659,481.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.